Several DOACs (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF.
Primary risk factors include older age, previous leg injury, deep venous thrombosis, and phlebitis.
WEB EXCLUSIVE: With the patents set to expire for a number of monoclonal antibodies, interest related to cancer biosimilars has expanded.
While positive outcomes with drugs and treatments require prompt intervention, ideally at the first sign of distress, about one-third of women do not experience chest pain when having a heart attack.
Nonprescription options that may be beneficial include immediate-release niacin, omega-3 fatty acids, and soluble fiber.